A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + IMRT for Locally Advanced Non-Metastatic SCC of the Oral Cavity/Oropharynx

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + IMRT for Locally Advanced Non-Metastatic SCC of the Oral Cavity/Oropharynx

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs GC 4419 (Primary)
  • Indications Mucositis
  • Focus Therapeutic Use
  • Sponsors Galera Therapeutics
  • Most Recent Events

    • 15 Jun 2017 Top-line results from this trial are expected in 4Q 2017 according to a Galera Therapeutics media release.
    • 15 Jun 2017 Status changed from recruiting to active, no longer recruiting according to a Galera Therapeutics media release.
    • 03 Feb 2016 According to a Galera Therapeutics Inc. media release, GC4419 received Fast Track designation for the prevention of radiation-related oral mucositis in patients with head and neck cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top